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Purpose: Patients with mesial temporal lobe epilepsy (MTLE) without MRI abnormalities
(MTLE-NL) represent a challenge for definition of underlying pathology and for presurgical
evaluation. In a recent study we observed significant amygdala enlargement (AE) in 14%
of MTLE patients with MRI signs of hippocampal sclerosis. Areas of gray matter volume
(GMV) increase could represent structural abnormalities related to the epileptogenic zone
or part of a developmental abnormality. Our objective was to look for undetected areas of
increased GMV in MTLE-NL using post processing MRI techniques to better understand
the pathophysiology of this condition.
Methods: We evaluated 66 patients with MTLE-NL on visual analysis and 82 controls.
Voxel-based morphometry (VBM) group analysis was performed with VBM8/SPM8 look-
ing for areas of increased GMV. We then performed automatic amygdala volumetry using
FreeSurfer software and T2 relaxometry to confirm VBM findings.
Results:Voxel-based morphometry group-analysis demonstrated increased amygdala vol-
ume in the MTLE-NL group compared to controls. Individual volumetric analysis confirmed
AE in eight (12%) patients. Overall, from all patients with AE and defined epileptic focus,
four (57%) had the predominant increased volume ipsilateral to the epileptic focus. These
results were cross-validated by a secondary VBM analysis including subgroups of patients
according to the volumetric data.T2 relaxometry demonstrated no amygdala hyperintense
signal in any individual with significant AE. There were no clinical differences between
patients with and without AE.
Discussion:This exploratory study demonstrates the occurrence of AE in 12% of patients
with MTLE-NL. This finding supports the hypothesis that there might be a subgroup of
patients with MTLE-NL in which the enlarged amygdala could be related to the epilepto-
genic process. Further studies are necessary but this finding could be of great importance
in the understanding of MTLE-NL.
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INTRODUCTION
Mesial temporal Lobe Epilepsy (MTLE) is frequently associated
with hippocampal sclerosis (HS), however there is a significant
group of patients with MTLE that do not have MRI signs of HS nor
other lesions on MRI visual analysis, the so called “MRI-negative”
patients (1).
Mesial temporal lobe epilepsy with normal MRI (MTLE-NL)
is a very challenging condition, especially when patients are under
evaluation for epilepsy surgery (2, 3). Patients with MTLE-NL
often show a different course of the disorder and worse surgical
outcome than patients with HS (4). MTLE-NL can be considered
a different syndrome from MTLE with HS (5). For MTLE-NL
patients it is still unknown whether there is lack of structural
abnormality or if there is an underlying cause that we still do
not understand.
Although no obvious epileptogenic lesion is detected on
MRI, many of these patients undergo temporal lobectomy after
appropriate presurgical evaluation (6–8) that usually includes
prolonged EEG recordings with intracranial electrodes. These pro-
cedures usually carry some risks and complications (9). Thus, the
use of non-invasive techniques looking for the possible underlying
cause of seizures in these patients could help the improvement of
surgical treatment. The use of post-process techniques to evaluate
subtle structural abnormalities in MR imaging of patients with
MTLE-NL have been used to look for areas of gray matter atro-
phy (2). However, areas of subtle diffuse atrophy can be related
to secondary damage rater than to the epileptogenic zone. On the
other hand, areas of gray matter increase could correlate better
with the epileptic focus in these patients. Indeed, in recent years, it
has become clear that MRI-negative epilepsies are not necessarily
non-lesional, the primary histopathological substrate being sub-
tle focal cortical dysplasia (FCD) (3, 10) which could be possibly
identified as subtle gray matter increase in specific post-process
MRI techniques (10, 11).
www.frontiersin.org October 2013 | Volume 4 | Article 166 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coan et al. Amygdala enlargement in MTLE
In a recent study of 102 MTLE patients with MRI signs of
HS, we observed significant amygdala enlargement (AE) in 14
(14%) individuals (12). Areas of gray matter increase in these
individuals could represent structural abnormalities related to the
epileptogenic zone or part of a developmental abnormality.
This exploratory study was designed to look for areas of sub-
tle gray matter increase in a group of MTLE-NL and to correlate
these findings with the clinical characteristics in these patients, in
order to better understand the pathophysiology of this condition.
We opted to perform initially a group analysis with the hypothesis
that we would be able to observe abnormalities of subgroups of
patients. As a secondary analysis, individual volumetry was per-
formed to isolate the patients in whom the abnormalities were
present.
MATERIALS AND METHODS
PATIENTS’ SELECTION
We included 66 patients with mean age of 41 years, [standard devi-
ations (SD), ±12.2 years, ranging from 19 to 74 years, 39 female]
who had clinical and electroencephalographic diagnosis of MTLE
with normal MRI on visual analysis and hippocampal volumet-
ric analysis. Thirteen patients (20%) were free of seizures for at
least 2 years and 53 (80%) had antiepileptic drug (AED) resistant
seizures. Patients were followed at the Epilepsy Clinic of the Uni-
versity of Campinas (UNICAMP). Prior to acquisition of MRI
data all patients signed an informed consent form approved by
the Ethics Committee of UNICAMP. For the neuroimaging analy-
sis we acquired 3D images, sagittal T1-weighted, with voxel size
of 1 mm× 1 mm× 1mm (TR= 7 ms, TE= 3.2 ms, flip angle= 8°,
matrix= 240× 240) in a 3 T MRI scanner (Philips Medical Sys-
tems, Best, The Netherlands) of all patients and of a control group
of 82 healthy subjects. All images underwent visual inspection and
only patients with normal MRI by visual analysis were selected. To
increase the specificity of the visual MRI analysis and to exclude the
individuals with subtle HS signs,we also performed automatic hip-
pocampal volume measurements in all patients and in 82 healthy
subjects using FreeSurfer software (version 5.1.01). Hippocam-
pal volumes were corrected for brain volumes of each individual.
Patients with hippocampal volumes lower than 2 SD (absolute
value and/or asymmetry index, defined by the ratio of smaller over
the larger hippocampus of each individual) from the mean of the
control group were excluded from this analysis. We collected clin-
ical information regarding sex, age, side of epileptic focus, age of
seizure onset, time of epilepsy, history of initial precipitate injury,
or status epilepticus, family history of epilepsy, occurrence of gener-
alized tonic-clonic seizures (GTCS), frequency of complex partial
seizures (CPS), and GTCS in the previous year.
VOXEL-BASED MORPHOMETRY
For voxel-based morphometry (VBM) we used the acquired 3D
images for patients and for a control group of 82 healthy sub-
jects. Pre-processing and statistical analysis were performed with
VBM8/SPM8 toolbox. The resultant gray matter images were
smoothed to remove large signals discrepancies between neigh-
boring voxels (10 mm FWHM). A test of quality was performed
1http://surfer.nmr.mgh.harvard.edu/
to observe homogeneity and co-registration between the data
and outliers were excluded from this study (three controls and
four with MTLE-NL). A two-sample t -test (p< 0.001, minimum
threshold cluster of 30 voxels) was performed between MTLE-NL
and controls.
AMYGDALA VOLUMETRY
To confirm VBM findings we performed amygdala volume (AV)
measurements in all patients and in 82 healthy subjects using
FreeSurfer software. AVs were corrected for brain volumes of each
individual. Patients with AVs lower or higher than 2 SD (absolute
value and/or asymmetry index, defined by the ratio of smaller
over the larger amygdala of each individual) from the mean of the
control group were considered abnormal. We also analyzed a sub-
group of patients with AVs between 1.5 and 2 SD from the mean
of controls.
We compared right and left AVs with the control group using a
t -test.
T2 RELAXOMETRY
T2 relaxometry of amygdala was performed in patients with
significant increase or decrease of amygdala volume to inves-
tigate signal abnormalities (higher than 2 SD of the mean of
the control group, composed by 82 healthy subjects). For this
analysis we used T2 multi-eco images (3 mm slices; TR= 3300;
TE= 30/60/90/120/150; matrix= 200× 176; FOV= 1802× 180)
and the in-house software Aftervoxel2.
CROSS-VALIDATION VBM ANALYSIS
In order to cross validate the VBM and volumetry we performed a
secondary VBM analysis based on groups defined by amygdala vol-
umetry. Because the binary definition of abnormally enlarged (>2
SD from controls) and normal (within 2 SD from controls) AVs
may include some individuals with less pronounced enlargement,
we included a third subgroup as follows:
1. MTLE-NL with AE higher than 2 SD from the mean of the
control group (enlarged amygdala volume).
2. MTLE-NL with AVs higher than 1.5 SD from the mean of
controls (borderline AE).
3. MTLE-NL with AVs lower than 1.5 SD from the mean of
controls (normal amygdala volume).
Pre-processing and statistical analysis were performed with
VBM8/SPM8 toolbox. The resultant gray matter images were
smoothed to remove large signals discrepancies between neigh-
boring voxels. A two-sample t -test (p< 0.05, FDR corrected; min-
imum threshold cluster of 30 voxels) was performed between the
described group and controls.
RESULTS
VBM GROUP ANALYSIS
The VBM z-score maps demonstrated increased gray mat-
ter volume (GMV) only in the left amygdala of MTLE-NL
group compared to controls (MNI coordinates: −24 −7 −21;
2http://www.liv.ic.unicamp.br/~bergo/aftervoxel
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T maximum= 3.69; number of contiguous voxels: 139). Details
of GM volume increase are show in Figure 1.
AMYGDALA VOLUMETRY
Individual volumetric analysis confirmed increased AVs in eight
(12%) MTLE-NL patients.
From the five patients with unilateral AE, two had the increased
amygdala ipsilateral to the epileptic focus, two contralateral, and
one had bitemporal EEG focus. From the three patients with bilat-
eral amygdala increase, two had the predominant side of increased
volume ipsilateral and one contralateral to the interictal EEG
abnormalities. Overall, from all patients with AE and defined
epileptic focus, four (57%) had the increased or predominantly
increased volume ipsilateral to the epileptic focus.
Five patients had borderline AE. None had significant decrease
of amygdala volume.
T2 RELAXOMETRY
T2 relaxometry demonstrated no amygdala hyperintense signal in
any individual with significant AE.
CLINICAL DATA
There were no clinical differences between the two groups (with
and without AE) regarding sex, age, age of seizure onset, family
history of epilepsy, history of initial precipitating injury, status
epilepticus, duration of epilepsy, AED response or occurrence of
GTCS in the previous year (Table 1). None of the patients with
enlarged amygdala underwent surgery and therefore pathological
specimens were not available.
CROSS-VALIDATION VBM GROUP ANALYSIS
The VBM z-score maps demonstrated bilateral increased amyg-
dala GMV in the enlarged amygdala group compared to controls
(Figure 2A).
The increased amygdala GMV was still present in the VBM
z-score maps when comparing controls to the borderline AVs
(Figure 2B).
The VBM analysis comparing controls to the patents with nor-
mal AVs did not show areas of increased gray matter (Figure 2C).
DISCUSSION
In this study we demonstrated an increase of the amygdala volume
in 12% of patients with MTLE-NL using two different methods.
The amygdala is known for its central role in emotional behavior
and it plays an important function in epilepsy and epileptogene-
sis (13, 14). The involvement of the amygdala in MTLE has been
largely investigated; however, its complete participation in MTLE
is still unknown (14). Findings such as stimulation of the amygdala
leading to experiential symptoms (15–17) as well as epileptiform
discharges arising from the amygdala in intracranial EEG record-
ings (18) are corroborating evidence of the importance of this
structure in MTLE. Studies with AVs in MRI-negative patients
have already been done and incidental cases of unexpected AE
have already been reported (14). Although the involvement of the
amygdala in MRI-negative MTLE has already been suggested, this
pattern was not observed in previous VBM studies, which could
be explained by the heterogeneity among MRI-negative patients
and small number of patients in previous studies.
The hypothesis that a subgroup of MTLE with amygdala
involvement may exist was already raised before (14, 18). Recently,
we demonstrated that a subgroup of patients with MTLE asso-
ciated with HS and early epilepsy onset have increased AVs,
and occasionally also hippocampal volumes, contralateral to the
epileptogenic zone (12). However, the frequency of this finding
and the clinical differences of patients with MTLE-NL with or
without abnormal amygdala volume have not been evaluated.
The results observed herein after individual automatic volumetry
analysis and after secondary VBM analysis strengthen this hypoth-
esis. Previous studies with MRI-negative epilepsies have shown
that there is indeed heterogeneity of epileptic pathologies in these
patients (3). Our finding probably points out the existence of a
subgroup of MTLE-NL with amygdala abnormalities. However,
the meaning of the increased volume of the amygdala remains
FIGURE 1 | Gray matter volume increase in patients with MTLE-NL. VBM
analysis looking for matter volume increase in patients with MTLE-NL
demonstrated significant amygdala enlargement on the left side (A,B) – glass
brain view. VBM, Two-sample t -test, p<0.001, minimum cluster size of 30
voxels. MTLE-NL, mesial temporal lobe epilepsy with normal MRI; VBM,
voxel-based morphometry;T,T score.
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Table 1 | Demographic and clinical data MTLE-NL patients with or without increased amygdala.
Normal amygdala (n=48) Increased amygdala (n=8) pValue
Sex M=26 M=1 p=0.081 (Pearson Chi-square)
Mean age (range) 41.7 (19–74 years) 47.6 (29–68 years) p=0.274 (t -test)
Mean age of seizure onset (range) 19.8 (2–48 years) 17.9 (8–47 years) p=0.702 (t -test)
Family history of epilepsy 29 3 p=0.507 (Pearson Chi-square)
IPI (FS) 12 (3) 2 (0) p=0.78 (Pearson Chi-square)
SE 1 0 p=0.708 (Pearson Chi-square)
Mean duration of epilepsy (range) 21.9 (1–50 years) 25.75 (15–48 years) p=0.144 (t -test)
Seizure remission 12 (25%) 1 (12.5%) p=0.585 (Pearson Chi-square)
Number of patients with SGTCS in the previous year 11 (23%) 1 (12.5%) p=0.657 (Pearson Chi-square)
MTLE-NL, mesial temporal lobe epilepsy with normal MRI; M, male; IPI, initial precipitating injury; FS, febrile seizure; SE, status epilepticus; SGTCS, secondary
generalized tonic-clonic seizures.
FIGURE 2 | SecondaryVBM group analysis. Secondary VBM analysis
confirmed the finding of subgroups of MTLE-NL patients with or without
amygdala enlargement detected by automatic volumetry. (A) VBM
demonstrated bilateral increased amygdala gray matter volume in the enlarged
amygdala group (N = 8); (B) VBM also detected increased amygdala gray
matter volume in the subgroup of patients with borderline amygdala volumes
(amygdala volumes z -score higher than 1.5 SD in the volumetric analysis;
N =14); (C) VBM analysis did not detected increase gray matter volumes in
the subgroup of patients with normal amygdala defined by the volumetric
analysis. VBM, Two-sample t -test, p<0.05, FDR corrected, minimum cluster
size of 30 voxels. MTLE-NL, mesial temporal lobe epilepsy with normal MRI;
VBM, voxel-based morphometry; FDR, false discovery rate;T,T score.
unknown. We could hypothesize that it may represent dyspla-
sia, dysgenesis, or other subtle structural abnormality. However
only further studies with pathological correlation would help us
understand this MRI finding.
Indeed, a series of 100 MTLE patients submitted to temporal
lobectomy with amygdalectomy and minimal hippocampal resec-
tion showed similar outcomes as compared to a series of 100 MTLE
patients submitted to temporal lobectomy with major hippocam-
pectomy in the same institution (19, 20). This and other series,
in addition to SEEG data (21, 22) supports the notion that some
patients with MTLE may have a major amygdalar seizure focus and
may not require removal of hippocampus. This would be partic-
ularly relevant for patients with normal MRI since these patients
are at high risk for memory decline after removal of a normal
appearing hippocampus on MRI. In a recent series of patients
who were submitted to a tailored resection sparing the hippocam-
pus they showed that 96.8% of patients did not have worsening of
post-operative memory performance (23).
The main limitation of the present study is that we did not have
ictal intracranial EEG recordings of these patients, nor surgical
treatment with pathological specimens. However, this preliminary
finding may give support for further investigations for defining
MRI surrogate markers of amygdala pathology and thus, helping
to identify patients who would benefit from a selective amyg-
dala removal sparring the hippocampus and parahippocampus.
In future studies, the amygdala volume should be investigated
in the pre-operatory MRI of patients with MTLE-NL who will
be submitted to anterior temporal lobe resections and special
attention should be given to the pathology of amygdala in these
individuals.
The results reported herein emphasize the possible role of the
amygdala in MTLE-NL, suggesting that there might be, at least in
some cases, a structural abnormality in the amygdala that may be
involved in some patients with MRI-negative MTLE. The enlarge-
ment of the amygdala could be the source of the pathology of these
individuals. Further studies are necessary but this preliminary
finding could be of great importance not only in the understanding
of MTLE-NL and also in the surgical treatment of this condition.
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